Nath Shivika, Saha Ambhrin, Srivastava Aarti
Department of Anesthesiology, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
Clin J Pain. 2022 Aug 1;38(8):528-535. doi: 10.1097/AJP.0000000000001052.
The aim was to evaluate the effect of oral administration of preoperative duloxetine on postoperative pain and total analgesic requirement in the postoperative period as the primary objective. The secondary objective was to evaluate the perioperative hemodynamic parameters, sedation scores, demographic data, and incidence of side effects (if any) in patients undergoing laparoscopic cholecystectomy.
This was a prospective, randomized, double-blind, placebo-controlled study conducted in a tertiary level medical college on 60 patients of either sex posted for laparoscopic cholecystectomies with American Society of Anesthesiologists (ASA) I and II. The patients were divided into 2 groups (n=30), the patients were given duloxetine 60 mg capsules and placebo capsules (Becosules) 2 hours before surgery.
The total requirement for both first and second rescue analgesics was higher in placebo as compared with duloxetine and was found to be significant ( P <0.05). The difference in mean visual analog scale score was significantly ( P <0.001) higher in placebo as compared with duloxetine at all-time intervals postoperatively 0 minute (7.6±0.7 vs. 4.6±0.8); 15 minutes (5.9±0.8 vs. 4.2±1.0); 30 minutes (4.4±0.5 vs. 3.6±0.9); 4 hours (6.6±0.06 vs. 5.3±1.3); 8 hours (5.2±1.2 vs. 3.9±1.0); and 12 hours (5.1±1.3 vs. 2.3±0.7). The mean arterial blood pressure and heart rate were significantly higher in placebo compared with duloxetine in most of the time intervals in the perioperative period. There was no significant difference in the sedation score between the groups except the 30 minutes and 8 hours postoperative.
Preoperative oral duloxetine during laparoscopic cholecystectomy could reduce postoperative pain, postoperative analgesic requirements, and better optimization of hemodynamics without causing major side effects.
主要目的是评估术前口服度洛西汀对术后疼痛及术后总镇痛需求的影响。次要目的是评估接受腹腔镜胆囊切除术患者的围手术期血流动力学参数、镇静评分、人口统计学数据及副作用发生率(如有)。
这是一项在三级医学院对60例拟行腹腔镜胆囊切除术、美国麻醉医师协会(ASA)分级为I级和II级的患者进行的前瞻性、随机、双盲、安慰剂对照研究。患者分为2组(每组n = 30),术前2小时分别给予患者度洛西汀60毫克胶囊和安慰剂胶囊(复合维生素胶囊)。
与度洛西汀组相比,安慰剂组首次和第二次补救镇痛药的总需求量更高,差异具有统计学意义(P < 0.05)。术后各时间点(0分钟:7.6±0.7 vs. 4.6±0.8;15分钟:5.9±0.8 vs. 4.2±1.0;30分钟:4.4±0.5 vs. 3.6±0.9;4小时:6.6±0.06 vs. 5.3±1.3;8小时:5.2±1.2 vs. 3.9±1.0;12小时:5.1±1.3 vs. 2.3±0.7),安慰剂组的平均视觉模拟量表评分均显著高于度洛西汀组(P < 0.001)。围手术期大多数时间间隔内,安慰剂组的平均动脉血压和心率显著高于度洛西汀组。除术后30分钟和8小时外,两组镇静评分无显著差异。
腹腔镜胆囊切除术前口服度洛西汀可减轻术后疼痛、降低术后镇痛需求,并更好地优化血流动力学,且无严重副作用。